Analysts Issue Forecasts for Aralez Pharmaceuticals’ Q1 2018 Earnings (ARZ)
Aralez Pharmaceuticals (TSE:ARZ) – Research analysts at Zacks Investment Research issued their Q1 2018 earnings per share estimates for shares of Aralez Pharmaceuticals in a research note issued to investors on Monday. Zacks Investment Research analyst D. Bautz anticipates that the company will post earnings per share of ($0.33) for the quarter. Zacks Investment Research also issued estimates for Aralez Pharmaceuticals’ Q2 2018 earnings at ($0.29) EPS, Q3 2018 earnings at ($0.16) EPS and Q4 2018 earnings at ($0.14) EPS.
Other equities research analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating on shares of Aralez Pharmaceuticals in a research report on Monday, February 5th. Bloom Burton downgraded Aralez Pharmaceuticals from a “buy” rating to an “accumulate” rating in a research report on Wednesday, March 14th.
Aralez Pharmaceuticals (TSE:ARZ) last issued its quarterly earnings data on Tuesday, March 13th. The company reported C($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of C($0.43) by C($0.05). Aralez Pharmaceuticals had a negative return on equity of 146.16% and a negative net margin of 100.42%. The business had revenue of C$35.59 million during the quarter, compared to analysts’ expectations of C$32.38 million.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.
Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.